Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2

Endocrine Pathology

Volumn 14, Issue 2, 2003, Pages 123-131

  Takami, Hiroshi ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

Calcitonin; Medullary thyroid carcinoma; Multiple endocrine neoplasia; RET protooncogene

Indexed keywords

AMINE OXIDASE (COPPER CONTAINING); BIOLOGICAL MARKER; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; CARCINOEMBRYONIC ANTIGEN; CORTICOTROPIN; GASTRIN RELEASING PEPTIDE; NEURON SPECIFIC ENOLASE; PROTEIN RET; SEROTONIN; SOMATOSTATIN; SUBSTANCE P; ONCOPROTEIN; PROTEIN TYROSINE KINASE; TUMOR MARKER;

CALCITONIN BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PREVENTION; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE MARKER; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HEALTH SURVEY; HUMAN; INHERITANCE; JAPAN; NEUROFIBROMATOSIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; QUESTIONNAIRE; SIPPLE SYNDROME; STATISTICAL SIGNIFICANCE; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; BLOOD; FEMALE; GENETICS; MALE; MEDULLARY CARCINOMA; MUTATION; PATHOLOGY; REVIEW; THYROID TUMOR;

CARCINOMA, MEDULLARY; FEMALE; HUMANS; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0142058082     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:14:2:123     Document Type: Conference Paper

References (55)

1. Soybel D, Wells SA Jr. Medullary thyroid carcinoma. In: Cady B, Rosshi RL, eds. Surgery of the thyroid and parathyroid glands, 1st ed. Philadelphia: WB Saunders, 1991; 152-178.
2. Clark OH. Medullary thyroid carcinoma. In: Clark OH, ed. Endocrine surgery of the thyroid and parathyroid glands, 1st ed. St. Louis, MO: CV Mosby, 1985; 91-105.
3. Saad MF, Ordnez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, Samaan NA. Medullary thyroid carcinoma, a study of the clinical features and prognostic factors in 161 patients. Medicine 63:319-342, 1989.
4. Girelli ME, Nacamulli D, Pelizzo MR, DeVido D, Mian C, Piccolo M, Busnard B. Medullary thyroid carcinoma, clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986. Thyroid 8:517-523, 1988.
5. Takami H, Hosoda Y. Current status of inherited medullary thyroid carcinoma in Japan. Oncol Rep 3:943-946, 1996.
6. Takami H. Current diagnosis and treatment of medullary thyroid carcinoma. Thyroidol Clin Exp 8:35-39, 1996.
7. Takami H, Bessho T, Kameya T, Mimura T, Ito K, Abe O, Hosoda Y, Shikata J. Immunohistochemical study of medullary thyroid carcinoma: relationship of clinical features to prognostic factors in 36 patients. World J Surg 12:572-579, 1988.
8. Moley JF. Medullary thyroid carcinoma and the multiple endocrine neoplasia type 2 syndromes. In: Doherty GM, Skogseid B, eds. Surgical endocrinology, 1st ed. Philadelphia: Lippincott Williams & Wilkins, 2001; 541-557.
9. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmor TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856, 1993.
10. Mulligan LM, Kwok JBJ, Healey CS, et al. Germline mutation of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460, 1993.
11. Hofstra RMW, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375, 376, 1994.
12. Shirahama S, Ogura K, Takami H, Ito K, Tohsen T, Miyauchi A, Nakamura Y. Mutatioinal analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma. J Hum Genet 43:101-106, 1998.
13. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA Jr, Goodfellow PJ, Donis-Keller H. Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 91:1579-1583, 1994.
14. Frank-Raue K, Höppner W, Frilling A, et al. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: Relation between genotype and phenotype. J Clin Endocrinol Metab 81:1780-1783, 1996.
15. Machens A, Gimm O, Hinze R, Höppner W, Boehm BO, Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma, oncological features and biochemical properties. J Clin Endocrinol Metab 86:1104-1109, 2001.
16. Ukkat J, Lorenz K, Hinze R, Thomusch O, Dralle H. Importance of early screening and prophylactic thyroidectomy in asymptomatic nonindex RET germline carriers. World J Surg 25:713-717, 2001.
17. Mendelsohn G, Wells SA Jr, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. Cancer 54:657-663, 1984.
18. Miyauchi A, Onishi T, Morimoto S, Takai S, Matuzaka F, Kuma K, Maeda M, Kumahara Y. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg 199:461-467, 1984.
19. Cohen R, Campos J-M, Salaün C, Heshmati HM, Kraimps J-L, Proye C, Sarfati E, Henry J-F, Niccoli-Sire P, Modigliani E. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. J Clin Endocrinol Metab 85:919-922, 2000.
20. Machens A, Gimm O, Ukkat J, Hinze R, Schneyer U, Dralle H. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 88:1909-1915, 2000.
21. Engelbach M, Görges R, Forst T, Pfützner A, Dawood R, Heerdt S, Kunt T, Bockisch A, Beyer J. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab 85:1890-1894, 2000.
22. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298:240-244, 1982.
23. Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, Vale WW, Evans RM. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304:129-135, 1983.
24. Craig RK, Hall L, Edbrooke MR, Allison J, Macinryre I. Partial nucleotide sequence of human calcitonin precursor mRNA identifies flanking cryptic peptides. Nature 295:345-347, 1982.
25. Takami H, Shikata J, Kakudo K, Ito K. Calcitonin gene-related peptide in patients with endocrine tumors. J Surg Oncol 43:28-32, 1990.
26. Takami H, Ito K. Calcitonin gene-related peptide as a tumor marker for medullary thyroid carcinoma. Int Surg 77:181-185, 1992
27. Greenspan FS. Medullary thyroid carcinoma. In: Clark OH, ed. Endocrine surgery of the thyroid and parathyroid glands. St. Louis, MO: CV Mosby, 1985; 98-107.
28. Takami H, Shikata J, Horie H, Sekine K, Ito K. PDN-21: possible tumor marker for medullary thyroid carcinoma. J Surg Oncol 44:205-207, 1990.
29. Takami H. Measurement of serum PDN-21 (Katacalcin) levels by radioimmunoassay in patients with various thyroid diseases. Exp Clin Endocrinol 102:370-373, 1994.
30. Takami H. Nationwide survey and analysis of the RET proto-oncogene in inherited medullary thyroid carcinoma in Japan. In: Utsunomiya J, Mulvihill M, Weber J, eds. Familial cancer and prevention, 1st ed. New York: Wiley-Liss, 1999; 371-375.
31. Takami H, Kameyama K, Hosoda Y. Nationwide survey of MEN type 2: results of a questionnaire distributed at the 28th meeting of the Japanese Society of Thyroid Surgery. Endocr Surg 13:1-8, 1996.
32. Takami H. Surgical management of medullary thyroid carcinoma. Geka (Jap J Surg) 58:671-674, 1996.
33. Brunt LM, Wells SA Jr. Advances in the diagnosis and treatment of medullary thyroid carcinoma. Surg Clin North Am 67:263-279, 1987.
34. Carney JA, Sizemore GW, Hayles AB. C-cell disease of the thyroid gland in multiple endocrine neoplasia, type 2b. Cancer 44:2173-2183, 1979.
35. Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Cancer 77:1556-1565, 1996.
36. Girelli ME, Nacamulli D, Pellizzo MR, Vido DD, Mian C, Picclolo M, Busnardo B. Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1696 and 1986. Thyroid 8:517-523, 1998.
37. Fuchshuber PR, Loree TR, Hicks WL Jr, Cheney RT, Shedd DP. Medullary carcinoma of the thyroid: prognostic factors and treatment recommendations. Ann Surg Oncol 5:81-86, 1998.
38. Kebebew E, Ituarte PHG, Duh QY, Clark OH. Medullary thyroid carcinoma, clinical characteristics, treatment, prognostic factors, and a comparison of staging system. Cancer 88:1139-1148, 2000.
39. Takami H. RET proto-oncogene mutation analysis for multiple endocrine neoplasia, type 2. Arch Surg 133:679, 1998.
40. Takiguchi-Shirahama S, Koyama K, Miyauchi A, Wakasugi T, Oishi S, Takami H, Hikiji K, Nakamura Y. Germline mutations of the RET proto-oncogene in eight Japanese patients with multiple endocrine neoplasia type 2A (MEN2A). Hum Genet 95:187-190, 1995.
41. Kitamura Y, Goodfellow PJ, Shimizu K, Nagahama M, Ito K, Kitagawa W, Akasu H, Takami H, Tanaka S, Wells SA Jr. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC. Oncogene 14:3103-3106, 1997.
42. Eng C, Mulligan LM. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Hum Mutat 9:97-109, 1997.
43. Mulligan LM. Multiple endocrine neoplasia type 2: molecular aspects. In: Dahia PLM, Eng C, eds. Genetic disorders of endocrine neoplasia. Basel: Karger, 2001; 81-102.
44. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET protooncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6:70-74, 1994.
45. Takami H. Management of medullary thyroid carcinoma. Thyroidol Clin Exp 10:59-65, 1998.
46. Takami H, Thosen T, Shirahama S, Ogura K, Hikiji K. Does the syndrome of familial medullary thyroid carcinoma describe a distinct clinical entity? Eur J Cancer 34:1639, 1640, 1998.
47. Takami H, Tohsen T. Familial medullary thyroid carcinoma unassociated with multiple endocrine neoplasia. Thyroidol Clin Exp 8:9-14, 1996.
48. Takami H, Niimi M, Ikeda Y Prognosis of a family with familial medullary thyroid carcinoma. J Exp Clin Cancer Res 18:223, 224, 1999.
49. Dralle H, Gimm O, Simon D, et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22:744-751, 1998.
50. Kebebew E, Tresler PA, Siperstein AE, Duh QY, Clark OH. Normal thyroid pathology in patients undergoing thyroidectomy for finding a RET gene germline mutation: A report of three cases and review of the literature. Thyroid 9:127-131, 1999.
51. Gimm O. Multiple endocrine neoplasia type 2: clinical aspects. In: Dahia PLM, Eng C, eds. Genetic disorders of endocrine neoplasia. Basel: Karger, 2001; 103-130.
52. Lecuba A, Hernandez C, Oriola J, Galard R, Gémar E, Mesa J, Simó R. V804M RET mutation and familial medullary thyroid carcinoma: report of a large family with expression of the disease only in the homozygous gene carriers. Surgery 509-514, 2002.
53. Schuffenecker I, Mond MV, Brohet R, et al. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Endocrinol Metab 83:487-491, 1988.
54. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium. JAMA 276:1575-1579, 1996.
55. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86: 5658-5671, 2001.